Acrivon Ebt Per Ebit from 2010 to 2024

ACRV Stock   6.55  0.11  1.71%   
Acrivon Therapeutics, Ebt Per Ebit yearly trend continues to be fairly stable with very little volatility. Ebt Per Ebit is likely to outpace its year average in 2024. During the period from 2010 to 2024, Acrivon Therapeutics, Ebt Per Ebit regression line of quarterly data had mean square error of  0.05 and geometric mean of  1.47. View All Fundamentals
 
Ebt Per Ebit  
First Reported
2010-12-31
Previous Quarter
0.89813644
Current Value
1.24
Quarterly Volatility
0.30592692
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 22.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.94. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Acrivon Therapeutics, Correlation against competitors.

Latest Acrivon Therapeutics,'s Ebt Per Ebit Growth Pattern

Below is the plot of the Ebt Per Ebit of Acrivon Therapeutics, Common over the last few years. It is Acrivon Therapeutics,'s Ebt Per Ebit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Ebt Per Ebit10 Years Trend
Slightly volatile
   Ebt Per Ebit   
       Timeline  

Acrivon Ebt Per Ebit Regression Statistics

Arithmetic Mean1.50
Geometric Mean1.47
Coefficient Of Variation20.38
Mean Deviation0.25
Median1.67
Standard Deviation0.31
Sample Variance0.09
Range0.7767
R-Value(0.73)
Mean Square Error0.05
R-Squared0.53
Significance0
Slope(0.05)
Total Sum of Squares1.31

Acrivon Ebt Per Ebit History

2024 1.24
2023 0.9
2022 0.95
2021 1.0

About Acrivon Therapeutics, Financial Statements

Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s Ebt Per Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebt Per Ebit 0.90  1.24 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.